Glyphic Bio

Glyphic Bio is a biotech company revolutionizing proteomics through next-generation protein sequencing technology. Founded in 2021 by Joshua Yang (CEO) and Daniel Estandian (CTO), the company emerged from MIT research. The company's mission is to decode the human proteome. Their platform tackles a major bottleneck in biotech: traditional protein sequencing methods are slow, biased toward highly expressed proteins, and can’t handle the full diversity of amino acids and modifications at scale. Glyphic’s solution uses a single-molecule, massively parallel approach, leveraging a novel molecule to detach and tether amino acids for identification. Instead of sequencing tens of thousands of proteins per week currently, Glyphic’s technology could sequence millions to tens of millions, potentially scaling to billions proteins.

Co-founders: Joshua Yang and Daniel Estandian